Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by Principal Financial Group Inc.

Principal Financial Group Inc. raised its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 740.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 86,440 shares of the biopharmaceutical company’s stock after purchasing an additional 76,150 shares during the quarter. Principal Financial Group Inc.’s holdings in Ultragenyx Pharmaceutical were worth $4,802,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in RARE. nVerses Capital LLC acquired a new stake in Ultragenyx Pharmaceutical in the 2nd quarter valued at approximately $33,000. True Wealth Design LLC bought a new position in shares of Ultragenyx Pharmaceutical in the third quarter worth $43,000. Values First Advisors Inc. acquired a new position in shares of Ultragenyx Pharmaceutical during the third quarter valued at $56,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Ultragenyx Pharmaceutical during the third quarter valued at about $83,000. Finally, Nomura Asset Management Co. Ltd. acquired a new stake in Ultragenyx Pharmaceutical in the third quarter worth about $93,000. Institutional investors own 97.67% of the company’s stock.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,465 shares of the company’s stock in a transaction that occurred on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total transaction of $393,853.40. Following the completion of the sale, the chief financial officer now owns 92,301 shares of the company’s stock, valued at $4,869,800.76. This represents a 7.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Emil D. Kakkis sold 11,727 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $42.23, for a total transaction of $495,231.21. Following the completion of the transaction, the chief executive officer now directly owns 2,183,985 shares in the company, valued at approximately $92,229,686.55. This represents a 0.53 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 27,465 shares of company stock valued at $1,302,735 over the last ninety days. Corporate insiders own 5.80% of the company’s stock.

Ultragenyx Pharmaceutical Stock Down 2.2 %

Ultragenyx Pharmaceutical stock opened at $41.15 on Friday. Ultragenyx Pharmaceutical Inc. has a 12 month low of $37.02 and a 12 month high of $60.37. The stock has a market cap of $3.80 billion, a P/E ratio of -6.36 and a beta of 0.56. The company’s fifty day simple moving average is $47.20 and its 200-day simple moving average is $49.32.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating analysts’ consensus estimates of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The firm had revenue of $139.49 million for the quarter, compared to the consensus estimate of $135.28 million. During the same quarter in the previous year, the company posted ($2.23) earnings per share. The business’s quarterly revenue was up 42.3% compared to the same quarter last year. On average, equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -6.2 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on RARE. Canaccord Genuity Group reiterated a “buy” rating and set a $121.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, November 12th. TD Cowen lifted their price target on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a research report on Monday, October 21st. HC Wainwright restated a “buy” rating and issued a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Tuesday, December 24th. JPMorgan Chase & Co. lowered their target price on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a report on Thursday, November 21st. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $77.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, Ultragenyx Pharmaceutical presently has a consensus rating of “Moderate Buy” and a consensus price target of $88.46.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.